Morphic Therapeutic, a Waltham, Mass.-based biotechnology company developing a new generation of oral integrin therapies, completed an $80m Series B financing.
The round was co-led by Omega Funds and Novo Holdings with participation from Invus and EcoR1 Capital and Series A investors. In connection with their investments, Otello Stampacchia, Ph.D., Managing Director at Omega Funds and Nilesh Kumar, Ph.D., Partner at Novo Ventures have joined Morphic’s Board of Directors.
The company intends to use the funds to advance its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
Led by Praveen Tipirneni, M.D., President & Chief Executive Officer, Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Founded on integrin biology innovations from the lab of scientific founder Tim Springer, Morphic has developed an exclusive platform to build on these discoveries, complemented by a partnership with computational chemistry leader Schrödinger, Inc., that facilitates the rapid and iterative design of clinical candidates.
Integrins are a ubiquitous family of receptors expressed on the surface of most human cells. Integrin signaling controls a wide range of cellular processes, including cell survival, cell cycle progression, immune system activation, cell differentiation and cell migration. Aberrant signaling contributes to a diverse array of human diseases, including each of Morphic Therapeutic’s focus areas of fibrosis, autoimmune diseases and immuno-oncology.